Sutent Adjunctive Treatment of Differentiated Thyroid Cancer

You may not qualify if:

• Patients who fulfill any of the following criteria will be excluded:
• Prior systemic chemotherapy or targeted therapy within 3 months prior to enrollment.
• Prior treatment on a Sutent clinical trial or current treatment on another clinical trial.
• Prior external beam radiation therapy to the target lesion(s).
• Life expectancy \< 3 months.
• History of any other carcinomas within the last 5 years, except cured basal cell carcinoma of the skin and cured in-situ cervical cancer.
• Serious uncontrolled concomitant disease that the Investigator feels might compromise study participation.
• Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome, or the inability to take oral medication.
• Any of the following clinical conditions within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, pulmonary embolism, ongoing cardiac dysrhythmias of NCI CTCAE grade at least 2, atrial fibrillation of any grade, or QTc interval \>450 msec for males or \>470 msec for females.
• Uncontrollable hypertension.
• Known human immunodeficiency virus infection.
• Current treatment with therapeutic doses of Coumadin-derivative anticoagulants (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
• Patients with a history of uncontrolled seizures, central nervous system disorders of psychiatric disability judged by the Investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake should be excluded from study.
• Inability to swallow whole tablets.
• Unwillingness to participate or inability to comply with the protocol for the duration of the study.